Allink Biotherapeutics announced today the completion of a $42 million Series A funding round. This round of financing is led by Lanchi Venture Capital, with follow-up investments from Yuansheng Venture Capital, Junlian Capital, and Jianfa Emerging Investment, as well as additional investments from existing shareholders Gao Rong Venture Capital and Mi Fang Health Fund. Gaorong Venture Capital co led the angel round of investment in AnLingKe Biotechnology in 2023.

AnLingKe Biotechnology was founded in 2023 and is a biotechnology company focused on innovative drug research and development. Based on its independently developed bispecific antibody and ADC technology platform, the company has laid out a series of innovative product pipelines with the potential for first in class (FIC) and best in class (BIC). The company is committed to developing breakthrough therapies in the fields of oncology and immune diseases, bringing innovative treatment options to patients worldwide.

AnLingKe Biology has established an efficient R&D and leadership team, with core members having over 20 years of experience in pharmaceutical chemistry, molecular biology, and translational medicine. Dr. Feng Hui, founder and CEO of AnLingKe Biotechnology, has nearly 20 years of experience in the research and management of large pharmaceutical companies. He led the development of Toripalimab, China's first PD-1 monoclonal antibody approved overseas.

This round of financing will help accelerate the global layout of AnLingKe Biotechnology, including advancing the Phase I clinical research of its core pipelines ALK201 and ALK202 in Australia, the United States, and China, actively expanding its research and development pipelines in the fields of oncology and immunology, continuously optimizing its independently developed bispecific antibody and ADC technology platform, and building a biotechnology company with global influence.

Over the past year since its establishment, the company has achieved a rapid leap from preclinical to clinical stages, "said Dr. Feng Hui, founder and CEO of AnLingKe Biotechnology." In the current financing environment of the biopharmaceutical industry, we are particularly grateful for the continued trust and support of our existing shareholders, and we are honored to welcome new investment partners who recognize our innovation capabilities and execution efficiency. With their support, we will be able to accelerate the development of innovative pipelines, including next-generation ADCs and bispecific antibodies, bringing new treatment hope to cancer and immune disease patients. In the coming months, we are expected to achieve multiple research and development milestones, which will further promote our mission of developing innovative therapies for patients

Dr. Yu Jiangtao, Managing Director of Gaorong Venture Capital, said, "As an angel round investor, we have witnessed the rapid growth of AnLingKe with our own eyes. The company's technological innovation in dual antibody and ADC platforms is remarkable, and its research and development pipeline is steadily advancing, achieving multiple breakthroughs. We are confident in the innovation strength and development potential of the AnLingKe team, and we are honored to continue to increase our support in Series A

The completion of this round of financing has opened a new chapter for the development of AnLingKe Biotechnology. Based on the efficient research and development capabilities of the company's innovative drugs and the foresight of the leadership team in the field of biomedicine, the funding support from Series A financing will help AnLingKe Biotechnology establish a leading position in the international competitive landscape of innovative drug research and development.